BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals develops oral small-molecule and injectable protein therapeutics for rare and specialized diseases. The company's marketed products include peramivir injection, an intravenous neuraminidase inhibitor for acute uncomplicated influenza sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU across different markets, and ORLADEYO, an oral serine protease inhibitor approved for hereditary angioedema treatment. These represent the company's primary revenue-generating assets.

The company maintains a pipeline of candidates in various development stages targeting rare immunological and allergic conditions. BCX10013, an oral Factor D inhibitor, is in development for complement-mediated diseases, while BCX17725, a protein therapeutic, is in phase 1 testing for Netherton syndrome. Additional programs include Avoralstat, an ocular plasma kallikrein inhibitor in preclinical development for diabetic macular edema, and oral C5 and C2 inhibitors for complement-related indications.

BioCryst operates as a moderate-scale biotechnology company with approximately 580 full-time employees and is headquartered in Durham, North Carolina. The company has established partnerships and in-license agreements with pharmaceutical entities including Shionogi & Co., Torii Pharmaceutical, and Green Cross Corporation, as well as research collaborations with government agencies including the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.